drugset / Trial / NCT07608354
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Timeline
- Start
- 2026-06-11
- Primary completion
- 2029-02-06
- Completion
- 2029-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALXN2220 | Unknown | — | Intravenous |
| Background | Eplontersen | Antisense oligonucleotide | — | Subcutaneous |